BioSpace News Archive

Despite a widely-touted recent joint pledge of prudence and caution on vaccine trial safety by nine drug companies working on COVID 19 vaccines, most fall far short on even the most basic transparency

The Centers for Medicare & Medicaid Services has awarded a four-year contract to IPRO to serve as a Hospital Quality Improvement Contractor within its Network of Quality Improvement and Innovation Contractors.

Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that they have entered into a definitive merger agreement to combine their businesses in an all-stock transaction.

LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Swedish, the largest nonprofit healthcare system in the Puget Sound region, today announced an agreement to extend their more than 20-year relationship.

BioIVT, a leading provider of research models and services for drug and diagnostic development, today launched its HEPATOMUNE® kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury.

Clinically meaningful and statistically significant improvement on CAPS-5 Arousal and Reactivity Score observed with NYX-783 Clinically meaningful improvement from baseline on CAPS-5 Total Score observed in 50 mg dose arm Statistically significant separation of 50 mg from placebo achieved on multiple measures of responder rate on CAPS-5 Total Score Observed safety and tolerability similar to placebo Data support discussion with FD

Shionogi to Present New Data on FETROJA ® (cefiderocol) at IDWeek 2020 Shionogi & Co., Ltd. (hereafter “Shionogi”) today announces that 18 abstracts on FETROJA ® (cefiderocol), including two oral presentations, will be shared at IDWeek™. The meeting will be held virtually from October 21-25. “These data reinforce our commitment to fighting antimicrobial resistance and further highlights th

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

In connection with its previously announced public offering of common shares in Canada and the United States, BELLUS Health Inc. announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies and Evercore ISI as joint book-running managers, and LifeSci Capital as co-manager, relating to the public offering of 15,555,556 common shares.

BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated January 17, 2020 (the “Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”).